Skip to main content

Main menu

  • Online first
    • Online first
  • Current issue
    • Current issue
  • Archive
    • Archive
  • Submit a paper
    • Online submission site
    • Information for authors
  • About the journal
    • About the journal
    • Editorial board
    • Information for authors
    • FAQs
    • Thank you to our reviewers
      • Thank you to our reviewers
    • American Federation for Medical Research
  • Help
    • Contact us
    • Feedback form
    • Reprints
    • Permissions
    • Advertising
  • BMJ Journals

User menu

  • Login

Search

  • Advanced search
  • BMJ Journals
  • Login
  • Facebook
  • Twitter
JIM

Advanced Search

  • Online first
    • Online first
  • Current issue
    • Current issue
  • Archive
    • Archive
  • Submit a paper
    • Online submission site
    • Information for authors
  • About the journal
    • About the journal
    • Editorial board
    • Information for authors
    • FAQs
    • Thank you to our reviewers
    • American Federation for Medical Research
  • Help
    • Contact us
    • Feedback form
    • Reprints
    • Permissions
    • Advertising

Effects of pharmacological reversal of hyperuricemia on features of the metabolic syndrome in patients with gouty arthritis

Mariana Marin, Naim M Maalouf
DOI: 10.1136/jim-2018-000728 Published 25 September 2018
Mariana Marin
1 Department of Internal Medicine, Divisions of Mineral Metabolism and Endocrinology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naim M Maalouf
2 Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, and Division of Mineral Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF
Loading

Abstract

Hyperuricemia has been associated in epidemiological studies with the development of obesity, hypertension, insulin resistance and type 2 diabetes. Nevertheless, it remains unclear whether lowering of serum uric acid (UA) alters any of the features of the metabolic syndrome. In this prospective study (ClinicalTrials.gov identifier: NCT01654276), 24 patients with gouty arthritis and hyperuricemia were treated for 6 months with the xanthine oxidase inhibitor febuxostat to lower serum UA to <6 mg/dL. Measurements of 24 hours ambulatory blood pressure (ABP) and serum and urine markers of the metabolic syndrome were measured at baseline and at the end of 6 months of febuxostat. The study population consisted of 18 men and 6 women, 18 of which completed the baseline and 6 months visits. Serum UA decreased significantly from 8.7±1.5 mg/dL at baseline to 4.4±1.1 mg/dL at 6 months (P<0.0001). During that time frame, there was no significant change in body mass index, systolic or diastolic blood pressure measured by 24 hours ABP monitor, serum glucose, insulin or homeostatic model assessment for insulin resistance, serum total and high-density lipoprotein-cholesterol, serum triglycerides or urine pH (P>0.05 for all). There was no correlation between parameters of the metabolic syndrome and the decline in serum UA or serum UA achieved at study end. In conclusion, in patients with gouty arthritis, UA lowering with febuxostat below 6 mg/dL had no significant impact on features of the metabolic syndrome.

Footnotes

  • Contributors MM contributed to subject recruitment, follow-up, data collection and drafting of manuscript. NMM contributed to subject recruitment, study conduct and supervision, data analysis and manuscript review.

  • Funding This study was funded in part by an investigator-initiated grant (MSA-NC-FEB-137) to Dr Maalouf from Takeda Pharmaceuticals (USA). This grant provided research costs to UT Southwestern.

  • Disclaimer Takeda Pharmaceuticals had no role (either direct or indirect) in study design, data collection and analysis, decision to publish or preparation of the manuscript. The authors had no other relationship or involvement with Takeda Pharmaceuticals.

  • Competing interests This study was funded in part by an investigator-initiated grant (MSA-NC-FEB-137) to Dr Maalouf from Takeda Pharmaceuticals (USA). This grant provided research costs to UT Southwestern.

  • Patient consent Obtained.

  • Ethics approval The study was reviewed and approved by the Institutional Review Board at the University of Texas Southwestern Medical Center.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

View Full Text

Log in using your username and password

Forgot your user name or password?

Log in through your institution

You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.

PURCHASE SHORT TERM ACCESS

Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$37.00

Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

PreviousNext
Back to top
Vol 66 Issue 7 Table of Contents
Journal of Investigative Medicine: 66 (7)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Front Matter (PDF)
Email

Thank you for your interest in spreading the word on JIM.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Effects of pharmacological reversal of hyperuricemia on features of the metabolic syndrome in patients with gouty arthritis
(Your Name) has sent you a message from JIM
(Your Name) thought you would like to see the JIM web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Effects of pharmacological reversal of hyperuricemia on features of the metabolic syndrome in patients with gouty arthritis
Mariana Marin, Naim M Maalouf
Journal of Investigative Medicine Oct 2018, 66 (7) 1031-1036; DOI: 10.1136/jim-2018-000728

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Cite This
  • APA
  • Chicago
  • Endnote
  • MLA
Loading
Effects of pharmacological reversal of hyperuricemia on features of the metabolic syndrome in patients with gouty arthritis
Mariana Marin, Naim M Maalouf
Journal of Investigative Medicine Oct 2018, 66 (7) 1031-1036; DOI: 10.1136/jim-2018-000728
Download PDF

Share
Effects of pharmacological reversal of hyperuricemia on features of the metabolic syndrome in patients with gouty arthritis
Mariana Marin, Naim M Maalouf
Journal of Investigative Medicine Oct 2018, 66 (7) 1031-1036; DOI: 10.1136/jim-2018-000728
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Respond to this article
  • Tweet Widget
  • Facebook Like
  • Google Plus One
  • Article
    • Abstract
    • Background
    • Methods
    • Results
    • Discussion
    • Conclusions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Hydration and obesity among outpatient-based population: H2Ob study
  • Thromboembolism peaking 3 months after starting testosterone therapy: testosterone–thrombophilia interactions
Show more Endocrinology/Metabolism

Similar Articles

 

CONTENT

  • Latest content
  • Current issue
  • Archive
  • Sign up for email alerts
  • RSS

JOURNAL

  • About the journal
  • Editorial board
  • Subscribe
  • Thank you to our reviewers
  • American Federation for Medical Research

AUTHORS

  • Information for authors
  • Submit a paper
  • Track your article
  • Open Access at BMJ

HELP

  • Contact us
  • Reprints
  • Permissions
  • Advertising
  • Feedback form

© 2022 American Federation for Medical Research